Teresa Macarulla
Hebron University
PathologyOncologyGemcitabineColorectal cancerMedicine
What is this?
Publications 242
#1Shalini Makawita (University of Texas MD Anderson Cancer Center)
#2Ghassan K. Abou-Alfa (Cornell University)H-Index: 38
Last. Teresa Macarulla (Hebron University)H-Index: 29
view all 16 authors...
Cholangiocarcinoma is an aggressive malignancy with poor overall survival. Approximately 15% of intrahepatic cholangiocarcinomas contain FGFR alterations. Infigratinib is an oral FGFR 1-3 kinase inhibitor. Favorable results from a Phase II trial of infigratinib in advanced/metastatic FGFR-altered cholangiocarcinomas has led to its further investigation in the front-line setting. In this article we describe the design, objectives and rationale for PROOF 301, a Phase III multicenter, open label, r...
#1Ghassan K. Abou-Alfa (Cornell University)H-Index: 38
#2Teresa Macarulla (Hebron University)H-Index: 29
Last. John BridgewaterH-Index: 32
view all 26 authors...
Summary Background Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 13% of patients with intrahepatic cholangiocarcinoma, a relatively uncommon cancer with a poor clinical outcome. The aim of this international phase 3 study was to assess the efficacy and safety of ivosidenib (AG-120)—a small-molecule targeted inhibitor of mutated IDH1—in patients with previously treated IDH1-mutant cholangiocarcinoma. Methods This multicentre, randomised, double-blind, placebo-controlled, phas...
2 CitationsSource
#1Bruno Bockorny (Harvard University)H-Index: 9
#2Valerya Semenisty (Rambam Health Care Campus)
Last. Katrina S. Pedersen (WashU: Washington University in St. Louis)H-Index: 5
view all 26 authors...
Programmed cell death 1 (PD-1) inhibitors have limited effect in pancreatic ductal adenocarcinoma (PDAC), underscoring the need to co-target alternative pathways. CXC chemokine receptor 4 (CXCR4) blockade promotes T cell tumor infiltration and is synergistic with anti-PD-1 therapy in PDAC mouse models. We conducted a phase IIa, open-label, two-cohort study to assess the safety, efficacy and immunobiological effects of the CXCR4 antagonist BL-8040 (motixafortide) with pembrolizumab and chemothera...
#1Zev A. Wainberg (UCLA: University of California, Los Angeles)H-Index: 32
#2Tanios Bekaii-Saab (Mayo Clinic)H-Index: 39
Last. Bin Zhang (Ipsen)H-Index: 1
view all 11 authors...
#1Elia Aguado (Agios Pharmaceuticals)H-Index: 2
#2Ghassan K. Abou-Alfa (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 38
Last. Shuchi Sumant Pandya (Agios Pharmaceuticals)H-Index: 11
view all 11 authors...
#1Lawrence H. Schwartz (Columbia University)H-Index: 45
#2Hedy L. Kindler (U of C: University of Chicago)H-Index: 57
Last. Dirk ArnoldH-Index: 27
view all 20 authors...
#1Robin L. Jones (The Royal Marsden NHS Foundation Trust)H-Index: 43
#2Teresa MacarullaH-Index: 29
Last. Patricia Roxburgh (Beatson West of Scotland Cancer Centre)H-Index: 8
view all 20 authors...
#1Helena VerdaguerH-Index: 3
Last. Javier Ros (Hebron University)H-Index: 1
view all 20 authors...
#1Milind Javle (University of Texas MD Anderson Cancer Center)H-Index: 30
#2Saeed Sadeghi (UCLA: University of California, Los Angeles)H-Index: 8
Last. Suebpong Tanasanvimon (Chula: Chulalongkorn University)H-Index: 3
view all 15 authors...
#1Jaime Feliu BatlleH-Index: 2
Last. Carmen Garcia Piernavieja (Hospital Universitario Insular de Gran Canaria)
view all 17 authors...